(Q36511588)

14 August 2017

1 reference

title

Botulinum neurotoxin - from laboratory to bedside (English)

1 reference

14 August 2017

Foster KA

1

1 reference

14 August 2017

Bigalke H

series ordinal

2

1 reference

14 August 2017

Aoki KR

series ordinal

3

1 reference

14 August 2017

publication date

1 April 2006

1 reference

14 August 2017

published in

Neurotoxicity Research

1 reference

14 August 2017

volume

9

1 reference

14 August 2017

issue

2-3

1 reference

14 August 2017

page(s)

133-140

1 reference

Evidence for antinociceptive activity of botulinum toxin type A in pain management

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Medical aspects of toxin weapons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

The mechanisms of vesicle budding and fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Botulinum neurotoxin B inhibits insulin-stimulated glucose uptake into 3T3-L1 adipocytes and cleaves cellubrevin unlike type A toxin which failed to proteolyze the SNAP-23 present

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Botulinum neurotoxin type B. Its purification, radioiodination and interaction with rat-brain synaptosomal membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Crystal structure of botulinum neurotoxin type A and implications for toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

How do tetanus and botulinum toxins bind to neuronal membranes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Mechanism of action of tetanus and botulinum neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Presynaptic receptor arrays for clostridial neurotoxins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Comparison of Clostridium botulinum toxins type D and C1 in molecular property, antigenicity and binding ability to rat-brain synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Botulinum toxins in pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Clinical comparability of marketed formulations of botulinum toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

SNAP receptors implicated in vesicle targeting and fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Clostridium botulinum types A, B, C1, and E produce proteins with or without hemagglutinating activity: Do they share common amino acid sequences and genes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Double-blind study of botulinum toxin in spasmodic torticollis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

The therapeutic use of botulinum toxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Botulinum type F neurotoxin. Large-scale purification and characterization of its binding to rat cerebrocortical synaptosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Binding of botulinum type Cl, D and E neurotoxins to neuronal cell lines and synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033931

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences

21 January 2018

1 reference

12 December 2020

Development of an in vitro bioassay for Clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay

1 reference

12 December 2020

Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins

1 reference

12 December 2020

A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function

1 reference

12 December 2020

In situ detection of the Clostridium botulinum type C1 toxin gene in wetland sediments with a nested PCR assay

1 reference

12 December 2020

Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles

1 reference

12 December 2020

Botulinum A toxins: units versus units

1 reference

12 December 2020

Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study

1 reference

12 December 2020

Inhibition of Clostridium botulinum types A and B hemagglutinins by sugars

1 reference

12 December 2020

Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms

1 reference

12 December 2020

Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis

1 reference

12 December 2020

A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

1 reference

12 December 2020

Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety

1 reference

12 December 2020

Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics

1 reference

12 December 2020

Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum a toxin

1 reference

12 December 2020

The 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Neurotoxins. Workshop review: assays and detection.

1 reference

12 December 2020

Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm

1 reference

12 December 2020

Detection of Clostridium botulinum types A, B, E and F in foods by PCR and DNA probe

1 reference

12 December 2020

Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA

1 reference

12 December 2020

Development of in vitro assays for the detection of botulinum toxins in foods

1 reference

12 December 2020

Observations on the isolated phrenic nerve diaphragm preparation of the rat.

1 reference

12 December 2020

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

1 reference

12 December 2020

A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03033931

1 reference

14 August 2017

1 reference